253840.KQ
Sugentech Inc.
KOE · Healthcare · Medical - Specialties · KR
KRW 4,315.00
+0.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.8B | 9.4B | 10.1B | 7.1B | 101.4B |
| Cost of Revenue | 8.7B | 10.4B | 11.3B | 13.0B | 58.7B |
| Gross Profit | 1.1B | (1.0B) | (1.2B) | (5.9B) | 42.7B |
| Operating Expenses | |||||
| R&D Expense | 4.4B | 4.4B | 4.6B | 3.6B | 5.2B |
| SG&A Expense | 7.5B | 5.2B | 5.4B | 12.9B | 12.3B |
| General & Admin Expense | 671.0M | 942.5M | 1.1B | 684.9M | 675.5M |
| Selling & Marketing Expense | 3.5B | 4.3B | 4.3B | 4.1B | 4.1B |
| Other Expenses | 9.1B | 8.1B | 10.8B | 10.2B | 9.0B |
| Total Operating Expenses | 19.9B | 17.8B | 20.8B | 16.5B | 17.4B |
| Cost and Expenses | 28.7B | 28.2B | 32.1B | 29.9B | 76.4B |
| Operating Income (EBIT) | (18.9B) | (18.8B) | (22.0B) | (22.7B) | 25.0B |
| Non-Operating | |||||
| Interest Income | 1.3B | 1.6B | 2.7B | 3.7B | 2.8B |
| Interest Expense | 1.3B | 638.0M | 501.2M | 1.8B | 2.1B |
| Net Interest Income | 35.4M | 972.2M | 2.2B | 1.8B | 675.1M |
| Other Non-Op Income/Expense | (4.2B) | (4.6B) | 1.2B | 4.0B | 7.4B |
| Non-Operating Income (excl Interest) | 4.5B | — | (1.7B) | (5.8B) | (9.5B) |
| EBT (Pre-Tax Income) | (23.1B) | (23.4B) | (20.8B) | (18.7B) | 32.3B |
| Income Tax Expense | 72.4M | 72.4M | (5.4B) | (1.3B) | 5.6B |
| Bottom Line | |||||
| Net Income | (23.0B) | (23.3B) | (15.2B) | (17.2B) | 26.7B |
| Earnings from Cont. Ops | (23.2B) | (23.5B) | (15.4B) | (17.4B) | 26.7B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (23.0B) | (23.3B) | (15.2B) | (17.2B) | 26.7B |
| Per Share | |||||
| Basic EPS | (₩1,428) | (₩1,403) | (₩993) | (₩1,090) | ₩1,686 |
| Diluted EPS | (₩1,428) | (₩1,403) | (₩993) | (₩1,071) | ₩1,509 |
| Revenue Per Share | ₩640 | ₩562 | ₩661 | ₩451 | ₩6,399 |
| Shares | |||||
| Basic Shares Outstanding | 15.3M | 16.7M | 15.3M | 15.8M | 15.8M |
| Diluted Shares Outstanding | 15.3M | 16.7M | 15.3M | 16.1M | 18.0M |
| Profitability Metrics | |||||
| EBITDA | (15.8B) | (15.6B) | (15.4B) | (12.1B) | 38.1B |
| D&A | 1.9B | 3.2B | 4.8B | 4.8B | 3.6B |
| EBIT | (17.7B) | (18.8B) | (20.3B) | (16.9B) | 34.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026